Q32 Bio is a biotechnology company developing therapies targeting powerful regulators of the innate and adaptive immune systems, with the goal of re-balancing the immune system in severe autoimmune and inflammatory diseases. Focused on the IL-7 pathway and complement system, Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $106M
Founded date: 2017
Investors 3
| Date | Name | Website |
| - | OrbiMed | orbimed.co... |
| - | Atlas Vent... | atlasventu... |
| 13.05.2022 | Abingworth... | abingworth... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 04.11.2020 | Series B | $60M | - |
| 27.05.2020 | Series A | $46M | - |
Mentions in press and media 17
| Date | Title | Description |
| 13.07.2026 | Alopecia Areata Drug Holds Hair Regrowth After Patients Stop Taking It | By Chase Fiorini Published: Jul 13 2026, 10:06 AM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 15.06.2026 | Hansa Biopharma appoints Adam Cutler as new Chief Financial Officer | Hansa Biopharma appoints Adam Cutler as new Chief Financial Officer Mon, Jun 15, 2026 07:00 CET Report this content Lund, Sweden, 15 June 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) announced today the appointment of Adam Cut... |
| 14.12.2024 | The Rise of nChroma Bio: A New Dawn in Genetic Medicine | In the world of biotechnology, mergers and funding are the lifeblood of innovation. Recently, two companies, Chroma Medicine and Nvelop Therapeutics, joined forces to create nChroma Bio. This new entity is set to redefine the landscape of g... |
| 08.12.2024 | Atlas Venture: $450 Million Fund XIV Closed To Invest In Biotech Innovation | Atlas Venture—a leading early-stage venture capital firm investing in biotech innovation—announced closing its fourteenth fund, raising $450 million in an oversubscribed fundraise. Through Fund XIV, Atlas Venture will continue collaborating... |
| 07.07.2021 | Q32 Bio Appoints Adam Cutler as Chief Financial Officer | |
| 04.11.2020 | Q32 Bio Raises $60M in Series B Financing | Q32 Bio, a Cambridge, Mass.-based biotechnology company developing biologic therapeutics to restore healthy immune regulation, closed a $60m Series B financing. The round was co-led by OrbiMed Advisors and Acorn Bioventures with participati... |
| 30.10.2020 | Q32 Bio secures US$ 60M in Series B funding | - |
| 29.10.2020 | Q32 Bio Scoops Up $60M Series B | CAMBRIDGE, MA, Q32 Bio, a biotechnology company developing biologic therapeutics to restore healthy immune regulation, today announced the completion of a $60 million Series B round. >> Click here for more funding data on Q32 Bio ... |
| 29.10.2020 | Q32 Bio Closes $60 Million Series B Financing, Advances to Clinical Stage Research in Therapeutics Designed to Restore Immune Homeostasis | |
| 29.10.2020 | Congratulations to Michael Broxson and team as Q32 Bio close a $60 Million Series B Financing, Advancing Clinical Stage Research in Therapeutics Designed to Restore Immune Homeostasis | - |
Show more